General Updates

June 30, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 NSE Symbol: GLENMARK BSE Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 26/26-27 Our Reference No. 26/26-27 Dear Sir/ Madam, Reg.: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sub: U.S. FDA inspection at Company’s manufacturing facility in Goa, India Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food & Drug Administration (U.S. FDA) conducted a GMP inspection at the Company’s Manufacturing Facility situated in Goa from June 22, 2026 to June 30, 2026. At the end of the inspection, the Company was issued a Form 483 with six observations. There was no observation related to data integrity reported. These observations are procedural in nature, and none are repeat observations. The Company does not anticipate any impact on the supply of its commercial products. The Company will work in close collaboration with the Agency to address the observations and will respond to the U.S. FDA within the stipulated timeline. We will keep the stock exchanges informed if there is any further update in this matter. We request you to take the above intimation on record. Thanking You. For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Glenmark Pharmaceuticals Limited Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com